At the core of IBI’s product line is the unique and flexible Verisome® platform. The Verisome® technology is a novel drug delivery system with very broad topical, systemic and ocular applications.
The ocular Verisome® products are uniquely positioned to treat ophthalmic diseases as they can be administered by injection and slowly deliver the drug as the Verisome® system simultaneously degrades. Delivery duration up to a year with a standard intravitreal injection has been demonstrated in human clinical trials.
The Verisome® drug delivery technology is the most advanced, yet simplest, system for controlling the release of therapeutic agents in the eye for extended periods of time. The Verisome® technology’s versatility can support a wide range of products individually formulated to meet the requirements of a given active agent and the demands of a specific clinical situation.